Main Page

OMNIJOURNAL

Peer-review by everyone

COVID-19 Pandemic

• Find More COVID-19 Papers
• Americas Frontline Doctors speak out (VIDEO)
• Gilead: Twenty-one billion reasons to discredit hydroxychloroquine (ORIGINAL ARTICLE)
• Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19
• Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
• Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19
• COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study
• Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
• Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea
• COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
• A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
• Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Recently Edited

• Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
• Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis
• Forty percent of people with coronavirus infections have no symptoms. Might they be the key to ending the pandemic
• Vitamin D deficiency causes a 10 times higher death rate in Covid-19 patients
• Early treatment with hydroxychloroquine: a country-randomized controlled trial
• Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
• An Effective Treatment for Coronavirus (COVID-19)
• Americas Frontline Doctors Peer Review
• Gilead: Twenty-one billion reasons to discredit hydroxychloroquine (ORIGINAL ARTICLE)
• Gilead: Twenty-one billion reasons to discredit hydroxychloroquine peer review
• COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study
• Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro